Home Latest Articles
Latest Articles
  • Xia WU, Jie WEN
    World Clinical Drug. 2018, 39(12): 809-812.

    Obesity is one of the risk factors of type 2 diabetes mellitus (T2DM). Therefore, effective weight management not only can improve blood glucose control, but also reduce the risk of vascular and microvascular complications. The weight management gradually receives more attention from all circles as an important part of diabetes mellitus comprehensive management. This review describes the weight management of T2DM patients.

  • Shan XU, Duan-duan HU, Rui CHEN, Zhi-ru XU, Li LIU
    World Clinical Drug. 2018, 39(12): 813-820.
    Objective

    To establish a high sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method for the determination of ginsenoside CK in the rats with middle cerebral artery occlusion (MCAO), and to study the pharmacokinetics parameters of ginsenoside CK in rats.

    Methods

    The plasma and brain tissue of rats were taken at different time points after single intragastric administration. Sample preparation was achieved by protein precipitation with methanol. Ginsenoside CK was detected by LC-MS/MS. The non-compartment model of DAS 2.0 software was used to calculate the pharmacokinetics parameters and the drug concentration in plasma and brain tissue in MCAO rats at different time points after administration.

    Results

    The method was linear over the range of 1~500 ng/ml with the lower limit of quantitation 1 ng/ml. The accuracy and precision of intra- and inter-day, recovery and stability of the method were all within the acceptable limits. Compared with the normal rats, the plasma t1/2 of the MCAO model rats was longer [(2.5+1.1) h vs (11.0±10.9) h], and the AUC value was higher [(14 944+2 170) ng/ml∙h vs (28 882+11 11 9) ng/ml∙h]; the Cmax of MCAO model rats was slightly lower [(2 834+768)ng/ml vs (2 634+638) ng/ml]. At the same time, the distribution of ginsenoside CK in the plasma of MCAO model rats was more than that in the brain tissue; the absorption of ginsenoside CK in normal rats was faster, and the blood concentration of ginsenoside CK was higher.

    Conclusion

    LC-MS/MS used for ginsenoside CK determination is a reliable approach. The low cerebral blood content of ginsenoside CK in MCAO model rats indicates that ginsenoside CK cannot penetrate the brain to effect.

  • Ya-ni SHI, Li-li ZHANG
    World Clinical Drug. 2018, 39(12): 821-825.
    Objective

    To investigate the risk factors for multidrug resistant bacteria (MDRB) infection in the patients with hemodialysis-associated pneumonia (HDAP).

    Methods

    A total of 105 patients with HDAP were enrolled in this study. Based on the results of germiculture, the patients were divided into MDRB group (n=24) and non-MDRB group (n=81). Multivariate Logistic regression analysis was used to examine the risk factors for MDRB infection in the patients with HDAP, and the receiver operating characteristics (ROC) curve was used to analyze the risk factors for predicting MDRB infection.

    Results

    The germicultures in 53 (50.48%) of 105 HDAP patients were positive, among which 24 cases were MDRB. The most common positive bacteria were Staphylococcus aureus (17 cases, 16.19%), Klebsiella pneumoniae (11 cases, 10.47%) and Streptococcus pneumoniae(9 cases, 8.57%). Multivariate Logistic regression analysis showed that the hospitalization in the last 3 months (OR=2.951, 95% CI: 1.022~8.518, P=0.045) and the pneumonia severity index (PSI) score (OR=1.023, 95% CI: 1.005~1.041, P=0.011) were independent risk factors for the MDRB infection in HDAP patients. The analysis of ROC curve for the prediction of the PSI score ≥147 points combined with hospitalization in the last 3 months showed that the sensitivity, specificity, positive predictive value, negative predictive value were 83.3%, 59.3%, 37.7% and 92.3% respectively.

    Conclusion

    For the patients with HDAP, they should prevent from MDRB infection if they have been hospitalized in the last 3 months and their PSI scores are more than 147 points.

  • Hong-mei ZHOU, Jin XU, Qing ZHANG, Qi ZHANG, Meng JIANG, Jun BU
    World Clinical Drug. 2018, 39(12): 826-831.
    Objective

    To observe the safety of dabigatran applied in elderly patients with atrial fibrillation and mild/moderate renal dysfunction after radiofrequency ablation.

    Methods

    A total of 94 elderly atrial fibrillation patients in hospital were selected, and divided into normal renal function group(n=27)and mild renal dysfunction group(n=51)and moderate renal dysfunction group(n=16)based on patients’ estimated glomerular filtration rate (eGFR). All three groups received radiofrequency ablation treatment, and the anticoagulant therapy started with dabigatran (110 mg twice a day) at 6 hours after operation. The renal and liver function and the blood cell data of these patients were measured at the before operation, 48 hours after operation and 1 month after operation. And three months continuous observation for the occurrence of embolization and hemorrhage was made.

    Results

    There were no major bleeding events in the three groups of patients, who received dabigatran as anticoagulant therapy. There was no significant difference in thromboembolic events among the three groups, and neither the reduction in liver and kidney function. In the three group patients treated with dabigatran, no peripheral blood cell reduction was observed.

    Conclusion

    As an anticoagulant, dabigatran can safely use for the elderly atrial fibrillation patients with mild/moderate renal dysfunction after radiofrequency ablation.

  • Xin CHEN, Shao-li CHU
    World Clinical Drug. 2018, 39(12): 832-835.
    Objective

    To investigate the hypertension management status including the medical equipment use, the anti-hypertensive drugs supply and drug rational use in Jiading community of Shanghai.

    Methods

    A total of 13 community health service centers in Jiading district of Shanghai were enrolled to perform the survey of hypertension management by the field investigation, questionnaires and on-the-spot investigation. The baseline data among the uncontrolled hypertensive patients in 13 community health service centers from April of 2016 to April of 2017 were randomly extracted, which included 502 hypertension patients. The zero-tail phenomenon and rational use of antihypertensive drugs were observed.

    Results

    Eleven of the 13 community health service centers were using mercury sphygmomanometers, and two using electronic and mercury sphygmomanometers. The 1 004 of blood pressure readings were from 76 general practitioners, and the zero preference of blood pressure accounted for 37.1%. There were 17 ambulatory blood pressure devices in 13 community health service centers, which were used to check 30 patients within 5 years. In 13 community health service centers, 29 kinds of first-line antihypertensive drugs were classified into five categories on average, and 2~4 kinds of traditional fixed compound preparations and only aldosterone receptor antagonists were used as second-line antihypertensive drugs. Among 923 prescriptions of antihypertensive drugs, 171 (18.5%) were unreasonable, 63 (36.8%) were using two similar drugs without indication, 45 (26.3%) were not using strong indications drugs, 28 (16.4%) were preferred second-line drugs without indication, and 20 (11.7%) were unreasonable using short-acting drugs.

    Conclusion

    The management of hypertension in primary health care centers in Jiading district of Shanghai is good, but the blood pressure measurement needs to be further standardized. The application of ambulatory blood pressure monitoring and electronic sphygmomanometer needs to be popularized urgently. Its antihypertensive drugs distribution is good, and the second-line antihypertensive drugs allocation is slightly inadequate. The rational use of antihypertensive drugs by community doctors needs to be improved.

  • Lei-ying HE, Xiao-ping SHI, Wei-hong CHEN, Dan-qing GAO, Ying-jie QIAN, Min-ya JIANG
    World Clinical Drug. 2018, 39(12): 836-838.
    Objective

    To study the occurrence and prognosis of abnormal liver function in the inpatients with psychiatric disorder.

    Methods

    A total of 847 psychiatric inpatients treated in Mental Health Center of Shanghai Jinshan District from January 2015 to December 2016 were included in this study. A retrospective study was conducted to analyze the incidence of abnormal liver function, etiology, liver damage caused by antipsychotic drugs and their prognosis.

    Results

    The incidence of abnormal liver function was 42.50% in psychiatric inpatients. The incidence of liver damage caused by antipsychotic drugs was 26.33%. The ranking of related liver damage drug was chlorpromazine>valproic acid>clozapine>olanzapine>perphenazine>risperidone>quetiapine>aripiprazole. After timely symptomatic treatment or adjusting the corresponding antipsychotic drugs treatment regimen, 84.75% of the patients were recovered to normal range within 3 months.

    Conclusion

    The incidence of abnormal liver function, especially drug-induced liver damage, is higher in psychiatric inpatients. Timely symptomatic treatment or the adjustment of corresponding liver damage drugs treatment has a relatively good prognosis.

  • Hong-wei DAI
    World Clinical Drug. 2018, 39(12): 839-842.
    Objective

    To analyze the effect of drug therapy combined with tobacco control management on blood pressure control and self-efficacy in the patients with essential hypertension.

    Methods

    A total of 400 patients with essential hypertension were included. Among them the smoking hypertension patients were randomly divided into two groups: the observation group (n=80) received drug treatment combined with tobacco control management, the control group 1 (n=100) only received drug treatment. On the other hand, the non-smoking hypertension patients as control group 2 (n=220) received drug treatment. All patients were followed up for 1 year. The blood pressure of all patients was recorded, and the self-efficacy of the patients was compared.

    Results

    The systolic blood pressure and diastolic blood pressure in observation group were lower than those in control group 1 (P<0.05), and were similar to those in control group 2. The excellent rate of blood pressure control in observation group was 93.75%, which was higher than that in control group 1 and control group 2 (P<0.05). The total score of self-efficacy in observation group was the highest, and the growth value was also the highest, which was significantly different from other two groups (P<0.05).

    Conclusion

    Drug therapy combined with tobacco control management not only can improve the blood pressure control, but also can improve the self-efficacy of patients with essential hypertension.

  • Guo-bei LIN, Hua-fei LUO
    World Clinical Drug. 2018, 39(12): 843-849.

    In recent years, more and more new carrier materials have been applied to the drug delivery systems, and many bottleneck problems have been resolved. This review summarizes the research status of various porous materials and carriers applied in transdermal drug delivery systems to provide a reference for formulations.

  • Chang-feng CHAI, Rui-hong HU, Xiao-ying BI
    World Clinical Drug. 2018, 39(12): 850-855.

    Oxcarbazepine is a new generation of antiepileptic drugs, which is approved as the monotherapy or adjunctive therapy for partial and secondarily generalised seizures. It can be used as a first-line drug for new diagnosis of epilepsy in adults. Pharmacogenomics studies had showed that the genes could affect oxcarbazepin pharmacokinetics. This review describes the oxcarbazepine from the pharmacogenomics point of view, including its action targets, catabolism, transport clearance and adverse reactions.

  • Jiang-xiong RUAN, Li-ping XIE, You-jia HU
    World Clinical Drug. 2018, 39(12): 856-863.

    Semaglutide is a long-acting human glucagon-like peptide-1 (GLP-1) receptor agonist, which can be used to assist in diet control and exercise to improve blood glucose in type 2 diabetes mellitus patients. This drug is available to be formulated as both subcutaneous and oral dosage form. Subcutaneous dosage forms are currently approved by FDA, and the oral dosage forms is still in the clinical phase Ⅲ stage. This article describes the mechanism, pharmacology, pharmacokinetics and clinical research progress of semaglutide.

News